Journals / Glokom Katarakt / 2021 / Cilt: 16 - Sayı: 1

Comparison of Early Results of Stand-alone XEN Gel Stent Implantation to Treat Pseudoexfoliative Glaucoma and Primary Open-angle Glaucoma

Pages
18–25
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In our study, stand-alone XEN® Gel Stent implantation produced no signifi cant difference in change in IOP or antiglaucoma medication usage between overall patients with POAG and PEXG, However, complete success rate was lower in the PEXG group.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To compare the postoperative outcomes of stand-alone XEN45® Gel Stent implantation in patients with pseudoexfoliative glaucoma (PEXG) and primary open-angle glaucoma (POAG).
📊
Key Findings & Data:Materials and Methods: This study included 69 eyes of 46 patients with POAG and 26 eyes of 17 patients with PEXG who had undergone XEN45® stent implantation.
💡
Conclusion & Impact:Conclusion: In our study, stand-alone XEN® Gel Stent implantation produced no signifi cant difference in change in IOP or antiglaucoma medication usage between overall patients with POAG and PEXG, However, complete success rate was lower in the PEXG group.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To compare the postoperative outcomes of stand-alone XEN45® Gel Stent implantation in patients with pseudoexfoliative glaucoma (PEXG) and primary open-angle glaucoma (POAG). Materials and Methods: This study included 69 eyes of 46 patients with POAG and 26 eyes of 17 patients with PEXG who had undergone XEN45® stent implantation. The inter- and intra-group changes in mean intraocular pressure (IOP), glaucoma medication requirements, needling rate, incidence of adverse effects, and success rate were analyzed. Results: There was no signifi cant intergroup difference in the mean IOP (p=0.326) or number of antiglaucoma medications (p=0.450) preoperatively. Both groups showed a signifi cant decrease in IOP and antiglaucoma medication usage at all postoperative time points, relative to the preoperative values. However, there was no signifi cant intergroup difference in the mean IOP or number of medications at any postoperative endpoint. In the POAG group (n=37) the mean preoperative IOP was 23.10±3.90 mmHg, with an average of 3.32±0.47 medications being used; these values decreased to 13.27±1.74 mmHg (42.5% decrease) and 0.70±1.24 (78.9% decrease) after 12 months of postoperative followup, respectively. Similarly, the mean IOP and number of medications used in the PEXG group (n=11) decreased from 22.63±3.23 mmHg and 3.18±0.60 preoperatively to 13.00±2.61 mmHg (42.5% decrease) and 1.27±1.49 (60% decrease) at 12 months postoperatively, respectively. Conclusion: In our study, stand-alone XEN® Gel Stent implantation produced no signifi cant difference in change in IOP or antiglaucoma medication usage between overall patients with POAG and PEXG, However, complete success rate was lower in the PEXG group.

🔖

Cite This Article

KARAPAPAK, M., OLGUN, A., DUZGUN, E., SENDUL, S. Y., GUVEN, D., ATMACA, F., KACAR, H., USTAOGLU, M. (2022). Comparison of Early Results of Stand-alone XEN Gel Stent Implantation to Treat Pseudoexfoliative Glaucoma and Primary Open-angle Glaucoma. Glokom Katarakt, Cilt: 16 - Sayı: 1, 18–25. https://ajindex.com/articles/525736

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Lewis RA. Ab interno approach to the subconjunctival space using a collagen glaucoma stent. J Cataract Refract Surg. 2014;40:1301-6
  2. Hengerer FH, Kohnen T, Mueller M, et al. Ab interno gel implant for the treatment of glaucoma patients with or without prior glaucoma surgery: 1-year results. J Glaucoma. 2017;26:1130- 36
  3. Schlenker MB, Gulamhusein H, Conrad-Hengerer I, et al. Effi cacy, safety, and risk factors for failure of standalone ab interno gelatin micro stent implantation versus standalone trabeculectomy. Ophthalmology. 2017;124:1579-88
  4. Grover DS, Flynn WJ, Bashford KP, et al. Performance and Safety of a New Ab Interno Gelatin Stent in Refractory Glaucoma at 12 Months. Am J Ophthalmol. 2017;183:25-36
  5. Mansouri K, Guidotti J, Rao HL, et al. Prospective Evaluation of Standalone XEN Gel Implant and Combined Phacoemulsifi cation-XEN Gel Implant Surgery: 1-Year Results. J Glaucoma. 2018;27:140-7
  6. Hohberger B, Welge-Lüßen UC, Lämmer R. MIGS: therapeutic success of combined XEN Gel Stent implantation with cataract surgery. Graefes Arch Clin Exp Ophthalmol. 2018;256:621-5
  7. Pérez-Torregrosa VT, Olate-Pérez Á, Cerdà-Ibáñez M, et al. Combined phacoemulsifi cation and XEN45 surgery from a temporal approach and 2 incisions. Arch Soc Esp Oftalmol. 2016;91:415-21
  8. De Gregorio A, Pedrotti E, Russo L, et al. Minimally invasive combined glaucoma and cataract surgery: clinical results of the smallest ab interno gel stent. Int Ophthalmol. 2018;38:1129-34
  9. Anastasopoulos E, Founti P, Topouzis F. Update on pseudoexfoliation syndrome pathogenesis and associations with intraocular pressure, glaucoma and systemic diseases. Curr Opin Ophthalmol. 2015;26:82-9
  10. Ritch R. Exfoliation syndrome-the most common identifi able cause of openangle glaucoma. J Glaucoma 1994; 3:176-7
  11. Ritch R, Schlötzer-Schrehardt U, Konstas AG. Why is glaucoma associated with exfoliation syndrome? Prog Retin Eye Res. 2003;22:253-75
  12. Conway RM, Schl€otzer-Schrehardt U, K€uchle M, et al. Pseudoexfoliation syndrome: pathological manifestations of relevance to intraocular surgery. Clin Exp Ophthalmol 2004; 32:199-210 13. Widder RA, Dietlein TS, Dinslage S, et al. The XEN45 Gel Stent as a minimally invasive procedure in glaucoma surgery: success rates, risk profi le, and rates of re-surgery after 261 surgeries. Graefes Arch Clin Exp Ophthalmol. 2018;256:765-71
  13. Ibáñez-Muñoz A, Soto-Biforcos VS, Chacón-González M, et al. One-year follow-up of the XEN® implant with mi